ClinicalTrials.gg
Active, not recruitingNCT07565597Updated Jun 8, 2026

A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.

A Phase 1 interventional study of Gecacitinib Hydrochloride Tablets in Healthy, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study will compare the pharmacokinetics (PK) effect of two different formulations of Gecacitinib Hydrochloride Tablets in healthy Adult participants

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd is the lead sponsor of 83 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18≤ age ≤ 45, male or female;
  • Body weight: ≥50 kg for male, ≥45 kg for female; (BMI): 19.0-26.0 kg/m\^2 (inclusive);
  • will be signed before the trial, and the content, process and possible adverse reactions of the study will be fully understood;
  • The volunteers should be able to communicate well with the researchers and understand and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Participants who were enrolled in a clinical trial or used a study drug within 3 months before administration of the study drug.
  • Participants may not be able to complete the study for other reasons or have other reasons for not participating in the study as judged by the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Test Group

    Participants will take a single Gecacitinib 75mg Tablet under fasting condition

    Drug: Gecacitinib Hydrochloride Tablets

  • Experimental
    Reference Group

    Participants will take a single Gecacitinib 75mg Tablet under fasting condition

    Drug: Gecacitinib Hydrochloride Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) Of Gecacitinib and its main metabolite ZG0244

    Time frame: up to 48 hours

  2. Gecacitinib and its main metabolite ZG0244 AUC(0-t)

    Time frame: up to 48 hours

  3. Gecacitinib and its main metabolite ZG0244 AUC(0-inf)

    Time frame: up to 48 hours

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Feb 2027, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 4, 2026
StartActual
May 12, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Mar 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07565597
Responsible party
Sponsor
First posted
May 4, 2026
Start date
May 12, 2026
Primary completion
Feb 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

Jason Wu
study chair · Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jaktinib

Start the discussion